The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
The study, titled “Structural and Functional Pulmonary MRI to Predict Pulmonary Exacerbations in Cystic Fibrosis,” analyzed imaging and clinical data from 106 individuals with CF who were imaged and ...
Cystic fibrosis causes a buildup of mucus in the lungs that can lead to infection, and often death in children and young ...
A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...
Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...
Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...
Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Generic drugs are supposed to be equivalent to brand-name medications — but the FDA doesn’t always ensure that.
New study finds cystic fibrosis drug allows patients to safely scale back lung therapies CU Anschutz researchers show that ETI treatment helps maintain lung health with fewer daily interventions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback